James E Talmadge (35 results)

paperback. Condition: Very Good. Free of markings.

Soft cover. Condition: Very Good to Fine. GGA - {Good Girl Art) Painted Cover (illustrator). First Collected Edition, PBO thus!. **FEATURE AND NOVELETS (1) Fit for a corpse by Brett Halliday **STORIES (1) Rubbish by Edward D.Hoch (2) Mother Love by Richard Deming (3) The beacon by Talmadge Powell (4) Faith unto death by Peter death (5) Personality conflict by Gary Alexandra (6) Salami on rye by Hal Ellson (7) Deadly Sunday by E.L Knouse (8) Another close call by Lenora K. Rogers (9) Outback by James M. Reasoner (10) Dont the windows look nice by Paul Young. >> Minor cover creaisng; Size: 12mo - over 6¾" - 7¾" tall. Book.

Soft cover. Condition: Fine. GGA - {Good Girl Art) Painted Cover (illustrator). First Collected Edition, PBO thus!. **FEATURE AND NOVELETS (1) Fit for a corpse by Brett Halliday **STORIES (1) Rubbish by Edward D.Hoch (2) Mother Love by Richard Deming (3) The beacon by Talmadge Powell (4) Faith unto death by Peter death (5) Personality conflict by Gary Alexandra (6) Salami on rye by Hal Ellson (7) Deadly Sunday by E.L Knouse (8) Another close call by Lenora K. Rogers (9) Outback by James M. Reasoner (10) Dont the windows look nice by Paul Young Size: 12mo - over 6¾" - 7¾" tall. Book.

Hardcover. Condition: Very Good - Cash. No Jacket. Thirteenth Edition 1924. Light rubbing and edge wear to cover, with light reader wear to pages. Body of text appears crisp clean and unmarked. Tight binding. Still great condition. Stock photos may not look exactly like the book.

Hardcover. Condition: Acceptable. Missing dust jacket; otherwise in excellent condition. Acceptable Condition. Five star seller - Buy with confidence!

Hardcover. Condition: Fair. No Jacket. Missing dust jacket; Readable copy. Pages may have considerable notes/highlighting. ~ ThriftBooks: Read More, Spend Less.

Condition: As New. Unread book in perfect condition.

Condition: New.

Leather. Condition: Very Good - Cash. Beautiful dark leather with vibrant gold text on the spine. Birthday inscription inside from 1926, other pages are unmarked. Some light general rubbing to the cover and pages. Red/Gold page edges. Stock photos may not look exactly like the book.

paperback. Condition: New. In shrink wrap. Looks like an interesting title!

Condition: New.

Condition: As New. Unread book in perfect condition.

hardcover. Condition: Acceptable. This is a used book. It may contain highlighting/underlining and/or the book may show heavier signs of wear . It may also be ex-library or without dustjacket. This is a used book. It may contain highlighting/underlining and/or the book may show heavier signs of wear . It may also be ex-library or without dustjacket.

Paperback. Condition: Brand New. 1st edition. 102 pages. 8.75x6.00x0.25 inches. In Stock.

Condition: New. In.

Condition: New. In.

PF. Condition: New.

Condition: New. pp. 212.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).

Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).

Hardcover. Condition: Very Good. Very Good. book.

Paperback. Condition: Like New. Like New. book.

Condition: Sehr gut. Zustand: Sehr gut | Seiten: 1455 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.

hardcover. Condition: Acceptable. Ex- Library no dust jacket medium wear to book edges and cover . Library stickers and stamps are present . Some corner dings.

Condition: new. Questo è un articolo print on demand.

Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Comprehensively explores the biology and role of MDSCs in cancerCovers therapeutic targeting via the STAT3 pathway, a major regulatory pathway in MDSCs functions as well as in tumour cellsParticularly relevant for scientists working in the .

Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6). 212 pp. Englisch.

Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search fo.

Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search fo.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6). 212 pp. Englisch.